These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 38627917)

  • 1. Circulating SMRP and CA-125 before and after pleurectomy decortication for pleural mesothelioma.
    Paajanen J; Sadek A; Richards WG; Xie Y; Mazzola E; Sidopoulos K; Kuckelman J; Gill RR; Bueno R
    Thorac Cancer; 2024 May; 15(15):1237-1245. PubMed ID: 38627917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble Mesothelin-Related Peptides to Monitor Recurrence After Resection of Pleural Mesothelioma.
    Burt BM; Lee HS; Lenge De Rosen V; Hamaji M; Groth SS; Wheeler TM; Sugarbaker DJ
    Ann Thorac Surg; 2017 Nov; 104(5):1679-1687. PubMed ID: 28964420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
    Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is soluble mesothelin-related protein an upfront predictive marker of pleural mesothelioma? A prospective study on Italian workers exposed to asbestos.
    Filiberti R; Marroni P; Spigno F; Merlo DF; Mortara V; Caruso P; Cioè A; Michelazzi L; Bruzzone A; Bobbio B; Simonassi C; Del Corso L; Galli R; Racchi O; Dini G; Linares R; Mencoboni M
    Oncology; 2014; 86(1):33-43. PubMed ID: 24401539
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma.
    Bonotti A; Simonini S; Pantani E; Giusti L; Donadio E; Mazzoni MR; Chella A; Marconi L; Ambrosino N; Lucchi M; Mussi A; Cristaudo A; Foddis R
    Int J Biol Markers; 2017 Mar; 32(1):e126-e131. PubMed ID: 27646775
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
    Ferro P; Canessa PA; Battolla E; Dessanti P; Franceschini MC; Chiaffi L; Morabito A; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2013 Jun; 33(6):2707-13. PubMed ID: 23749930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peritoneal Dissemination in Patients with Recurrence After Post-pleurectomy/decortication for Pleural Mesothelioma.
    Nakamura A; Hashimoto M; Kuroda A; Takegahara K; Fukuda A; Matsumoto S; Kondo N; Minami T; Kitajima K; Kuribayashi K; Kijima T; Funaki S; Hasegawa S
    Ann Surg Oncol; 2024 Nov; 31(12):7767-7774. PubMed ID: 39126438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Soluble mesothelin-related peptides levels in patients with malignant mesothelioma.
    Franko A; Dolzan V; Kovac V; Arneric N; Dodic-Fikfak M
    Dis Markers; 2012; 32(2):123-31. PubMed ID: 22377706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic.
    Jakubec P; Pelclova D; Smolkova P; Kolek V; Nakladalova M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Sep; 159(3):472-9. PubMed ID: 24781044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
    Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
    Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions.
    Pass HI; Wali A; Tang N; Ivanova A; Ivanov S; Harbut M; Carbone M; Allard J
    Ann Thorac Surg; 2008 Jan; 85(1):265-72; discussion 272. PubMed ID: 18154821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
    Hassan R; Sharon E; Thomas A; Zhang J; Ling A; Miettinen M; Kreitman RJ; Steinberg SM; Hollevoet K; Pastan I
    Cancer; 2014 Nov; 120(21):3311-9. PubMed ID: 24989332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between tumor MSLN methylation and serum mesothelin (SMRP) in mesothelioma.
    Nelson HH; Almquist LM; LaRocca JL; Plaza SL; Lambert-Messerlian GM; Sugarbaker DJ; Bueno R; Godleski JJ; Marsit CJ; Christensen BC; Kelsey KT
    Epigenetics; 2011 Aug; 6(8):1029-34. PubMed ID: 21775819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of TGF-β in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma.
    Stockhammer P; Ploenes T; Theegarten D; Schuler M; Maier S; Aigner C; Hegedus B
    Lung Cancer; 2020 Jan; 139():124-132. PubMed ID: 31778960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
    Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
    J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Correlation of Serum Mesothelin Level With Pleural Thickness in Malignant Pleural Mesothelioma Makes it a Valuable Tool for Monitoring Tumor Progression.
    Fontana V; Vigani A; Pistillo MP; Giannoni U; Rosemberg I; Canessa PA; Berisso G; Ferro P; Franceschini MC; Tonarelli M; Roncella S
    J Thorac Oncol; 2019 May; 14(5):e92-e94. PubMed ID: 31027749
    [No Abstract]   [Full Text] [Related]  

  • 17. Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial.
    Katz SI; Roshkovan L; Berger I; Friedberg JS; Alley EW; Simone CB; Haas AR; Cengel KA; Sterman DH; Albelda SM
    Lung Cancer; 2021 Apr; 154():5-12. PubMed ID: 33561782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure.
    Rodríguez Portal JA; Rodríguez Becerra E; Rodríguez Rodríguez D; Alfageme Michavila I; Quero Martínez A; Diego Roza C; León Jiménez A; Isidro Montes I; Cebollero Rivas P
    Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):646-50. PubMed ID: 19190155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two novel polymorphisms in 5' flanking region of the mesothelin gene are associated with soluble mesothelin-related peptide (SMRP) levels.
    Cristaudo A; Foddis R; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Bruno R; Gemignani F; Landi S
    Int J Biol Markers; 2011; 26(2):117-23. PubMed ID: 21574151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High dose irradiation after pleurectomy/decortication or biopsy for pleural mesothelioma treatment.
    Parisi E; Romeo A; Sarnelli A; Ghigi G; Bellia SR; Neri E; Micheletti S; Dipalma B; Arpa D; Furini G; Burgio MA; Genestreti G; Gurioli C; Sanna S; Bovolato P; Rea F; Storme G; Scarpi E; Arienti C; Tesei A; Polico R
    Cancer Radiother; 2017 Dec; 21(8):766-773. PubMed ID: 29132803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.